Principia BioPharma
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 5.0m | 69.0m | 35.0m | 50.0m | 75.0m | 25.0m |
| % growth | - | 1280 % | (49 %) | 43 % | 50 % | (67 %) |
| EBITDA | - | 17.0m | (56.0m) | (57.0m) | (165m) | (207m) |
| % EBITDA margin | - | 25 % | (160 %) | (114 %) | (220 %) | (828 %) |
| Profit | - | 4.0m | (53.0m) | (126m) | (195m) | (271m) |
| % profit margin | - | 6 % | (151 %) | (252 %) | (260 %) | (1084 %) |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $12.1m | Series A | |
$12.5m | Series A | ||
$50.0m | Series B | ||
$15.3m | Late VC | ||
$50.0m | Series C | ||
| N/A | $106m Valuation: $386m 77.2x EV/LTM Revenues | IPO | |
* | N/A | $210m | Post IPO Equity |
$3.7b Valuation: $3.7b 105.1x EV/LTM Revenues -65.7x EV/LTM EBITDA | Acquisition | ||
| Total Funding | AUD216m | ||
Related Content
Recent News about Principia BioPharma
EditPrincipia Biopharma is a biopharmaceutical company focused on developing innovative drug candidates for immune-mediated diseases. The company operates in the biotechnology sector, targeting conditions such as multiple sclerosis, pemphigus, and immune thrombocytopenia. Principia's core technology, tailored covalency, allows for the creation of highly selective and novel small molecules that differentiate their drug candidates from conventional therapies. The business model involves advancing these drug candidates through clinical trials, with the goal of achieving regulatory approval and commercialization. Revenue is generated through partnerships, licensing agreements, and eventual product sales. Principia primarily serves patients with unmet medical needs, healthcare providers, and pharmaceutical companies looking for advanced treatment options.
Keywords: biopharmaceutical, immune-mediated diseases, tailored covalency, multiple sclerosis, pemphigus, immune thrombocytopenia, clinical trials, drug candidates, biotechnology, healthcare.